文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症呼吸衰竭与机械通气

右美托咪定对脓毒症机械通气患者死亡率和无呼吸机天数的影响:一项随机临床试验

Effect of Dexmedetomidine on Mortality and Ventilator-Free Days in Patients Requiring Mechanical Ventilation With Sepsis: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01
一句话结论在脓毒症机械通气患者中,使用右美托咪定镇静与不使用相比,28天死亡率及28天无呼吸机天数均无统计学显著差异。

该研究为在日本8个ICU开展的多中心、开放标签随机临床试验,纳入201例需机械通气至少24小时的成人脓毒症患者,随机分为右美托咪定组(n=100)和对照组(n=101)。主要终点为28天死亡率和28天无呼吸机天数,结果两组均无统计学显著差异(死亡率22.8% vs 30.8%,HR 0.69,95%CI 0.38-1.22,P=0.20;无呼吸机天数中位数20 vs 18天,P=0.20)。右美托咪定组机械通气期间镇静控制良好率显著更高(范围17%-58% vs 20%-39%,P=0.01)。作者结论认为右美托咪定未显著改善死亡率或无呼吸机天数,但研究可能对死亡率把握度不足,可能需要进一步研究评估。

要点

  • 在脓毒症机械通气患者中,右美托咪定组28天死亡率为22.8%(19例),对照组为30.8%(28例),HR 0.69(95%CI 0.38-1.22,P=0.20),无统计学显著差异。
  • 28天无呼吸机天数右美托咪定组中位数20天(IQR 5-24),对照组18天(IQR 0.5-23),P=0.20,无统计学显著差异。
  • 右美托咪定组机械通气期间镇静控制良好率显著高于对照组(范围17%-58% vs 20%-39%,P=0.01)。
  • 不良事件发生率右美托咪定组8%(8例),对照组3%(3例)。
  • 作者认为研究可能对死亡率把握度不足,可能需要进一步研究评估。

适用人群与场景

  • 日本8个ICU中201例成人脓毒症患者,需机械通气至少24小时,年龄均值69岁(SD 14岁),63%为男性。

处置流程与药物剂量

  • 右美托咪定组接受右美托咪定镇静,对照组接受不含右美托咪定的镇静;两组其他用药包括芬太尼、丙泊酚和咪达唑仑。

研究设计与关键结果

  • 研究类型:开放标签、多中心随机临床试验,在日本8个ICU开展,2013年2月至2016年1月,筛查203例,随机201例(右美托咪定组n=100,对照组n=101)。
  • 主要终点:28天死亡率右美托咪定组22.8%(19例)vs 对照组30.8%(28例),HR 0.69(95%CI 0.38-1.22,P=0.20),无统计学显著差异;28天无呼吸机天数右美托咪定组中位数20天(IQR 5-24)vs 对照组18天(IQR 0.5-23),P=0.20,无统计学显著差异。
  • 关键次要终点:右美托咪定组机械通气期间镇静控制良好率显著更高(范围17%-58% vs 20%-39%,P=0.01);其他次要结局两组无显著差异。
  • 不良事件:右美托咪定组8例(8%),对照组3例(3%)。

证据类型、等级与局限

  • 证据类型:多中心随机临床试验(开放标签)。
  • 局限:研究可能对死亡率把握度不足,可能需要进一步研究评估。

对床旁实践的改变

  • 对于脓毒症需机械通气的成人患者,使用右美托咪定镇静与不使用相比,未显著改善28天死亡率或28天无呼吸机天数;作者认为研究可能对死亡率把握度不足,可能需要进一步研究评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Dexmedetomidine provides sedation for patients undergoing ventilation; however, its effects on mortality and ventilator-free days have not been well studied among patients with sepsis.

OBJECTIVES: To examine whether a sedation strategy with dexmedetomidine can improve clinical outcomes in patients with sepsis undergoing ventilation.

DESIGN, SETTING, AND PARTICIPANTS: Open-label, multicenter randomized clinical trial conducted at 8 intensive care units in Japan from February 2013 until January 2016 among 201 consecutive adult patients with sepsis requiring mechanical ventilation for at least 24 hours.

INTERVENTIONS: Patients were randomized to receive either sedation with dexmedetomidine (n = 100) or sedation without dexmedetomidine (control group; n = 101). Other agents used in both groups were fentanyl, propofol, and midazolam.

MAIN OUTCOMES AND MEASURES: The co-primary outcomes were mortality and ventilator-free days (over a 28-day duration). Sequential Organ Failure Assessment score (days 1, 2, 4, 6, 8), sedation control, occurrence of delirium and coma, intensive care unit stay duration, renal function, inflammation, and nutrition state were assessed as secondary outcomes.

RESULTS: Of the 203 screened patients, 201 were randomized. The mean age was 69 years (SD, 14 years); 63% were male. Mortality at 28 days was not significantly different in the dexmedetomidine group vs the control group (19 patients [22.8%] vs 28 patients [30.8%]; hazard ratio, 0.69; 95% CI, 0.38-1.22; P = .20). Ventilator-free days over 28 days were not significantly different between groups (dexmedetomidine group: median, 20 [interquartile range, 5-24] days; control group: median, 18 [interquartile range, 0.5-23] days; P = .20). The dexmedetomidine group had a significantly higher rate of well-controlled sedation during mechanical ventilation (range, 17%-58% vs 20%-39%; P = .01); other outcomes were not significantly different between groups. Adverse events occurred in 8 (8%) and 3 (3%) patients in the dexmedetomidine and control groups, respectively.

CONCLUSIONS AND RELEVANCE: Among patients requiring mechanical ventilation, the use of dexmedetomidine compared with no dexmedetomidine did not result in statistically significant improvement in mortality or ventilator-free days. However, the study may have been underpowered for mortality, and additional research may be needed to evaluate this further.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01760967.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Kawazoe Y, Miyamoto K, Morimoto T, et al. Effect of Dexmedetomidine on Mortality and Ventilator-Free Days in Patients Requiring Mechanical Ventilation With Sepsis: A Randomized Clinical Trial. JAMA. 2017. PMID: 28322414. doi:10.1001/jama.2017.2088

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。